Series C+ · 2026-11-04 · Healthcare
bit.bio raises $25.0M
58
AI Score
Amount
$25.0M
Round
Series C+
Lead
Not disclosed
HQ
GB
Why it matters: The round shows investors backing scalable human cell models as AI-driven drug discovery raises demand for consistent, reproducible test systems.
Human cell programming company bit.bio closed a $25 million Series D.
- Participants:
- M&G Investments, Jonathan Milner
- Source:
- Tech.eu ↗ · Midu summary
Deal Dossier PRO
Pro feature
Deal Dossier for bit.bio
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing